AstraZeneca (LON:AZN) Receives Sell Rating from Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN – Get Free Report)‘s stock had its “sell” rating reaffirmed by equities researchers at Deutsche Bank Aktiengesellschaft in a report released on Thursday,London Stock Exchange reports. They currently have a £115 target price on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price target would suggest a potential downside of 17.56% from the company’s previous close.

Several other research firms also recently weighed in on AZN. Jefferies Financial Group reaffirmed a “buy” rating and issued a £180 price target on shares of AstraZeneca in a research note on Wednesday, May 13th. Berenberg Bank raised their target price on AstraZeneca from £145 to £160 and gave the company a “buy” rating in a research note on Tuesday, January 27th. Finally, Citigroup boosted their target price on AstraZeneca from £170 to £180 and gave the company a “buy” rating in a research report on Friday, April 10th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of £153.33.

Get AstraZeneca alerts:

View Our Latest Research Report on AZN

AstraZeneca Price Performance

AZN remained flat at £139.50 during trading on Thursday. 41,023,766 shares of the company’s stock were exchanged, compared to its average volume of 34,744,191. The company has a quick ratio of 0.59, a current ratio of 0.91 and a debt-to-equity ratio of 71.66. The company has a 50 day simple moving average of £143.13 and a 200-day simple moving average of £140.81. AstraZeneca has a twelve month low of £101.03 and a twelve month high of £157.32. The stock has a market capitalization of £216.34 billion, a PE ratio of 21.01, a PEG ratio of 0.86 and a beta of 0.22.

About AstraZeneca

(Get Free Report)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Featured Stories

• Five stocks we like better than AstraZeneca
• 2 Software Stocks Turning AI Fears Into Fundamental Gains
• The Token Takeover: SEC Triggers Market Quake
• Target Shows Strengths, But Analysts Want to See More
• NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.